Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 2,087 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Hemophilia A, Hemophilia B
Interventions: PF-06741086; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Year to 74 Years · Male only
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 4
States / cities: Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Dyslipidemia
Interventions: Evolocumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 5,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 144
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 136 more

Conditions: Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
Interventions: Placebo for Linaclotide, Linaclotide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 38
States / cities: Foley, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 33 more

Conditions: Friedreich's Ataxia
Interventions: GV101, Placebo; Drug
Lead sponsor: Graviton Bioscience Corporation; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: HIV Infections
Interventions: Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 16
States / cities: San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more

Conditions: Melanoma
Interventions: Ipilimumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 19
States / cities: Tucson, Arizona • Laverne, California • Los Angeles, California + 15 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Frexalimab, Placebo, Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 14
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more

Conditions: Osteoporosis
Interventions: ALX1-11; Drug
Lead sponsor: Shire; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 9
States / cities: Beverly Hills, California • Chicago, Illinois • Detroit, Michigan + 6 more

Conditions: Heart Transplant Rejection, Graft Failure, Compliance, Patient
Interventions: Envarsus; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Psoriatic Arthritis
Interventions: TILD sub-cutaneous (SC) injection; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 41
States / cities: Dothan, Alabama • Gilbert, Arizona • Mesa, Arizona + 36 more

Conditions: Brain Edema, Brain Tumor
Interventions: hCRF [XERECEPT (corticorelin acetate injection)]; Drug
Lead sponsor: Celtic Pharma Development Services; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 25
States / cities: Phoenix, Arizona • Newport Beach, California • Palo Alto, California + 20 more

Conditions: Macular Degeneration, Age-Related, Geographic Atrophy
Interventions: Galegenimab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 48
States / cities: Bakersfield, California • Encino, California • Fullerton, California + 43 more

Conditions: Retinopathy of Prematurity (ROP)
Interventions: Ranibizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more

Conditions: AL Amyloidosis
Interventions: NEOD001; Drug
Lead sponsor: Prothena Biosciences Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 16
States / cities: Duarte, California • Denver, Colorado • Jacksonville, Florida + 13 more

Conditions: Muscular Dystrophy, Duchenne
Interventions: SRP-5051; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Sacramento, California • Gulf Breeze, Florida • Atlanta, Georgia + 4 more

Conditions: Ulcerative Colitis
Interventions: RPC1063; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 10
States / cities: Tucson, Arizona • Anaheim, California • Mission Hills, California + 7 more

Conditions: Plaque-type Psoriasis
Interventions: Placebo, Secukinumab 150mg, Secukinumab 300mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: LPCN 1144; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Roseville, California • Ocoee, Florida • Las Vegas, Nevada + 6 more

Conditions: Pyruvate Kinase Deficiency
Interventions: Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 12
States / cities: Phoenix, Arizona • Oakland, California • Atlanta, Georgia + 8 more

Conditions: β-thalassemia, Ineffective Erythropoiesis
Interventions: PTG-300; Drug
Lead sponsor: Protagonist Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Oakland, California • Boston, Massachusetts

Conditions: Healthy
Interventions: Tapentadol ER 250-mg TRF tablet, Tapentadol ER 250-mg PR2 tablet; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Autism Spectrum Disorder
Interventions: Balovaptan; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 4 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Phoenix, Arizona • Staten Island, New York • Cleveland, Ohio + 2 more

Conditions: Schizophrenia and Related Disorders
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: Columbia University; Other
Eligibility: 22 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation, Stroke
Interventions: dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 12
States / cities: La Mesa, California • Pensacola, Florida • Port Charlotte, Florida + 9 more

Search by objective public record fields.

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

GV101 for Friedreich's Ataxia (FA) Treatment

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

Open Label Extension

Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Rainbow Extension Study

Study in Subjects With Light Chain (AL) Amyloidosis

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

Safety Study for Beta Thalassemia Subjects on PTG-300

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder

An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048